APA (7th ed.) Citation

X, Z., T, Z., T, W., FH, H., BT, B., R, L., . . . JT, S. (2020). Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma. International journal of cancer, 147(10), 2847. https://doi.org/10.1002/ijc.33137

Chicago Style (17th ed.) Citation

X, Zhang, et al. "Characterization of a Dual BET/HDAC Inhibitor for Treatment of Pancreatic Ductal Adenocarcinoma." International Journal of Cancer 147, no. 10 (2020): 2847. https://doi.org/10.1002/ijc.33137.

MLA (9th ed.) Citation

X, Zhang, et al. "Characterization of a Dual BET/HDAC Inhibitor for Treatment of Pancreatic Ductal Adenocarcinoma." International Journal of Cancer, vol. 147, no. 10, 2020, p. 2847, https://doi.org/10.1002/ijc.33137.